First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
ICOS 激动剂 Vopratelimab 单独和与 Nivolumab 联合治疗的首次人体 I/II 期 ICONIC 试验：ICOS 高 CD4 T 细胞群和反应预测因子
期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-21-4256
Timothy A Yap, Justin F Gainor, Margaret K Callahan, Gerald S Falchook, Russell K Pachynski, Patricia LoRusso, Shivaani Kummar, Geoffrey T Gibney, Howard A Burris, Scott S Tykodi, Osama E Rahma, Tanguy Y Seiwert, Kyriakos P Papadopoulos, Mariela Blum Murphy, Haeseong Park, Amanda Hanson, Yasmin Hash
